Diagnostic and prognostic value of serum vitronectin levels in human glioma

Abstract Objective Vitronectin is an extracellular matrix protein, the synthesis of which by glioma cells correlates with tumor grade. The current study was designed to investigate the relationship between serum vitronectin levels and clinicopathological characteristics, diagnosis and prognosis in g...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 2016-12, Vol.371, p.54-59
Main Authors: Chen, Mao-Hua, Lu, Chuan, Sun, Jun, Chen, Xian-Dong, Dai, Jun-Xia, Cai, Jian-Yong, Chen, Xiang-Lin
Format: Article
Language:English
Subjects:
Adult
Age Factors
Aged
Biomarkers, Tumor - blood
Brain Neoplasms - blood
Brain Neoplasms - mortality
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Diagnosis
Disease Progression
Female
Glioma
Glioma - blood
Glioma - mortality
Glioma - pathology
Glioma - therapy
Humans
Male
Middle Aged
Neoplasm Grading
Neurology
Prognosis
Prospective Studies
Serum vitronectin
Survival Analysis
Treatment Outcome
Tumor Burden
Vitronectin - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective Vitronectin is an extracellular matrix protein, the synthesis of which by glioma cells correlates with tumor grade. The current study was designed to investigate the relationship between serum vitronectin levels and clinicopathological characteristics, diagnosis and prognosis in glioma patients. Methods In a prospective observatory study, a total of 98 glioma patients, 98 healthy controls, 98 other non-glioma brain tumors, and 98 other non-tumor neurological diseases were recruited. Following univariate analyses, multivariate analyses were performed to explore the associations of serum vitronectin levels with survival and clinicopathological parameters. Receiver operating characteristic curve analysis was done to assess its diagnostic and prognostic predictive value. Results Serum vitronectin levels were significantly elevated in glioma patients as compared with other groups. High Wealth Health Organization grade was independently associated with high vitronectin levels. Serum vitronectin levels could significantly distinguish glioma patients from other groups and discriminate high-grade glioma from low-grade glioma. Vitronectin levels markedly predicted 5-year progression and 5-year mortality. Moreover, serum vitronectin was identified as an independent predictor for 5-year overall survival and 5-year progression-free survival as well as 5-year mortality and 5-year progression. Conclusion Serum vitronectin may be a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.
ISSN:0022-510X
1878-5883
DOI:10.1016/j.jns.2016.10.022